WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...
Kymera Therapeutics, Inc. announced that it will release results from its Phase 1 clinical trial of KT-621, an investigational oral degrader medicine targeting the STAT6 transcription factor linked to ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported ...
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen ...
Kymera Therapeutics announced new clinical trials for KT-621, targeting atopic dermatitis and asthma, with data expected in 2025 and 2026. Kymera Therapeutics has announced the initiation of patient ...
Shares of Kymera Therapeutics KYMR were up 41.6% yesterday after the company announced positive data from the phase Ib BroADen study, which evaluated its lead pipeline candidate KT-621 for treating ...
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback